Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 743,279
  • Shares Outstanding, K 142,664
  • Annual Sales, $ 175,510 K
  • Annual Income, $ -78,020 K
  • 60-Month Beta 1.36
  • Price/Sales 4.26
  • Price/Cash Flow N/A
  • Price/Book 2.08
Trade AUPH with:

Options Overview Details

View History
  • Implied Volatility 49.48% ( -5.67%)
  • Historical Volatility 39.91%
  • IV Percentile 2%
  • IV Rank 10.69%
  • IV High 123.04% on 10/09/23
  • IV Low 40.67% on 03/25/24
  • Put/Call Vol Ratio 0.51
  • Today's Volume 1,002
  • Volume Avg (30-Day) 1,726
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 62,558
  • Open Int (30-Day) 59,230

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.01
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate 0.00
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +112.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.77 +9.22%
on 04/25/24
5.93 -12.07%
on 05/20/24
+0.18 (+3.58%)
since 04/24/24
3-Month
4.71 +10.62%
on 04/18/24
6.12 -14.87%
on 02/27/24
-0.74 (-12.44%)
since 02/23/24
52-Week
4.71 +10.62%
on 04/18/24
12.43 -58.09%
on 07/28/23
-5.23 (-50.10%)
since 05/24/23

Most Recent Stories

More News
Why Aurinia Pharmaceuticals Stock Is Slumping Today

The biotech's premium valuation doesn't seem to be sitting well with investors.

AUPH : 5.21 (-0.57%)
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

The biotech's board is exploring strategic alternatives to boost shareholder value.

NVS : 100.53 (-0.57%)
BMY : 41.24 (-0.72%)
AUPH : 5.21 (-0.57%)
S&P Futures Climb Ahead of Key U.S. Inflation Data

September S&P 500 futures (ESU23) are trending up +0.33% this morning as market participants awaited a reading on the Federal Reserve’s preferred inflation gauge.

ESU23 : 4,491.72s (-0.32%)
WFC : 60.21 (+0.89%)
JPM : 200.71 (+1.92%)
BAC : 39.70 (+1.35%)
OXY : 61.95 (-0.02%)
MU : 129.49 (+2.55%)
ENGI.P.DX : 15.435 (-0.32%)
NKE : 91.75 (+0.38%)
ACCD : 7.37 (+2.79%)
AUPH : 5.21 (-0.57%)
CCL : 15.13 (+2.37%)
NVDA : 1,064.69 (+2.57%)
MKT Capital Issues Statement Regarding Aurinia’s Disappointing First Quarter 2023 Financial Results

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial...

AUPH : 5.21 (-0.57%)
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 25% and 24.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 5.21 (-0.57%)
HRTX : 3.44 (-0.86%)
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.

AUPH : 5.21 (-0.57%)
ISS Recommends Aurinia Shareholders Vote Against the Company’s Named Executive Officers’ Compensation

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial...

AUPH : 5.21 (-0.57%)
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option...

AUPH : 5.21 (-0.57%)
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 11.11% and 7.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RIGL : 0.9075 (+0.49%)
AUPH : 5.21 (-0.57%)
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that...

AUPH : 5.21 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

3rd Resistance Point 5.44
2nd Resistance Point 5.36
1st Resistance Point 5.29
Last Price 5.21
1st Support Level 5.13
2nd Support Level 5.05
3rd Support Level 4.98

See More

52-Week High 12.43
Fibonacci 61.8% 9.48
Fibonacci 50% 8.57
Fibonacci 38.2% 7.66
Last Price 5.21
52-Week Low 4.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar